I am Vice President Business Unit Lead for US hematology and nephrology rare diseases at Alexion, AstraZeneca Rare Disease. I have the privilege of working with a passionate and talented team of colleagues focused on addressing the needs of patients suffering from often overlooked or misunderstood conditions - like paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS). I am motivated by the potential to help these patient communities - both through the medicines we bring to market today, and by the development programmes that continue to progress in these therapeutic areas.

I joined AstraZeneca by way of Alexion, which I joined in 2019. The opportunity to be part of a rare disease focused biotech business unit represents a capstone to experiences I’ve been fortunate to have across 25 years with biotech, pharmaceutical and medical device organisations, spanning a range of therapeutic areas and stages in product lifecycle.

I am currently responsible for strategy, operations, and financial performance of the business unit I lead. This business unit is comprised of a cross-functional team of colleagues dedicated to facilitating timely and accurate diagnosis as well as treatment of indicated diseases, through awareness and education. Prior to joining Alexion, AstraZeneca Rare Disease, I served in various general management (e.g., Business Unit Lead, Country Manager) and functional leadership roles (e.g., Marketing, Sales, Account Management). Before these commercial roles, I had been Director of Worldwide Regulatory Strategy with responsibility for pre- and post-approval programmes for various biopharmaceutical, device, and combination products.


Inspired by the patients we have met, my team strives to deliver an exceptional experience for those patients managing their rare disease.

John P. Kennedy VP/BU Lead, US Hematology/Nephrology Rare Disease Division

2020

Alexion Guiding Star Award

2019

Alexion Guiding Star Award


CURRENT ROLE

Vice President/Business Unit Lead, US Hematology/Nephrology Rare Disease at Alexion, AstraZeneca Rare Disease

2017 - 2019

Vice President/Business Unit Lead, US Biosimilars at Pfizer

2016-2017

Country Manager, Czech Republic at Pfizer

2013 - 2016

Regional Business Director, US Midwest/Northwest at Pfizer


Veeva ID: Z4-42741
Date of preparation: March 2022